SCHEMBL5230928

SCHEMBL5230928

N#Cc1cnn2c(Cl)c(-c3ccccc3Cl)c(Cl)nc12

nearest known ligand 0.43

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
KDM4D Q6B0I6 1/20 0.43
CSNK2A1 P68400 7/20 0.42
KDM4E B2RXH2 5/20 0.42
ALDH1A1 P00352 5/20 0.42
HPGD P15428 4/20 0.42
GLA P06280 1/20 0.42
MAPK1 P28482 1/20 0.42
HSD17B10 Q99714 1/20 0.42
LMNA P02545 1/20 0.41
POLB P06746 1/20 0.41
RXFP1 Q9HBX9 1/20 0.41
CNR1 P21554 2/20 0.40
CNR2 P34972 2/20 0.40
NPSR1 Q6W5P4 1/20 0.39
CLK4 Q9HAZ1 1/20 0.39
CDK2 P24941 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
HTT P42858 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4691830 0.83 CSNK2A1 (0.46) KDM4DCSNK2A1KDM4EALDH1A1HPGD
SCHEMBL4695582 0.81 CSNK2A1 (0.39) KDM4DCSNK2A1KDM4EALDH1A1HPGD
SCHEMBL14464266 0.78 CSNK2A1 (0.42) KDM4DCSNK2A1KDM4EALDH1A1HPGD
SCHEMBL14463716 0.78 KDM4E (0.48) KDM4DCSNK2A1KDM4EALDH1A1HPGD
SCHEMBL4695906 0.77 CDK2 (0.40) KDM4DCSNK2A1KDM4EALDH1A1HPGD
SCHEMBL4695611 0.75 CSNK2A1 (0.41) KDM4DCSNK2A1KDM4EALDH1A1HPGD
SCHEMBL5323810 0.74 KDM4E (0.44) KDM4DCSNK2A1KDM4EALDH1A1HPGD
SCHEMBL5594559 0.74 CSNK2A1 (0.43) KDM4DCSNK2A1KDM4EALDH1A1HPGD
SCHEMBL18863648 0.73 CDK2 (0.45) KDM4DCSNK2A1KDM4EALDH1A1HPGD
SCHEMBL5438939 0.73 CDK2 (0.48) KDM4DCSNK2A1KDM4EALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1513843-B1 PYRAZOLOPYRIMIDINES AND THE USE THEREOF FOR CONTROLLING HARMFUL ORGANISMS BAYER CROPSCIENCE AG (DE) 2007-07-04 EP disclosed
US-20060089499-A1 Pyrazolopyrimidines and the use thereof for controlling harmful organisms UWW VENTURES UNLIMITED (GB) 2006-04-27 US disclosed
EP-1513843-A1 PYRAZOLOPYRIMIDINES AND THE USE THEREOF FOR CONTROLLING HARMFUL ORGANISMS Bayer CropScience AG (DE) 2005-03-16 EP disclosed
WO-2004000844-A1 PYRAZOLOPYRIMIDINES AND THE USE THEREOF FOR CONTROLLING HARMFUL ORGANISMS BAYER CROPSCIENCE AKTIENGESELLSCHAFT (DE) 2003-12-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060089499-A1 Pyrazolopyrimidines and the use thereof for controlling harmful organisms PRDX1, PRDX2, PRDX5 KDM4D 2676/4885CSNK2A1 2382/4885KDM4E 3455/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.